MS4A1 and acute lymphoblastic leukemia: Fortunately, the addition of CD20 monoclonal antibodies such as rituximab to chemotherapy regimens have prolonged the survival of Philadelphia chromosome (Ph)‐negative B‐lineage ALL (B‐ALL) patients who are CD20+ [13].